Vivelle-Dot

Atrophic Vaginitis, Low Testosterone, Hypogonadism + 27 more

Treatment

5 FDA approvals

20 Active Studies for Vivelle-Dot

What is Vivelle-Dot

Estradiol

The Generic name of this drug

Treatment Summary

Estradiol is a naturally occurring hormone that is used in hormone therapy products to treat conditions related to low estrogen, such as vaginal dryness and hot flashes. It is available in multiple forms, including oral tablets, injections, vaginal rings, patches, sprays, gels, and creams. To increase its effectiveness when taken orally or injected, estradiol is usually combined with an ester side-chain. One common form of estradiol is ethinyl estradiol (EE), which is the estrogenic component of most combination birth control pills. EE has a higher bioavailability and is less susceptible to metabolism than est

Estraderm

is the brand name

image of different drug pills on a surface

Vivelle-Dot Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Estraderm

Estradiol

1986

373

Approved as Treatment by the FDA

Estradiol, also known as Estraderm, is approved by the FDA for 5 uses like Hormonal Contraception and Breast Cancer .

Hormonal Contraception

Used to treat Hormonal Contraception therapy in combination with Levonorgestrel

Breast Cancer

Birth Control

Used to treat Contraception in combination with Levonorgestrel

Palliative Treatment

Breast Cancer

Effectiveness

How Vivelle-Dot Affects Patients

Estradiol helps to reduce symptoms of hot flashes, vaginal dryness, and pain during sex. It can also help to increase bone density, reduce harmful cholesterol levels, and increase levels of certain proteins in the liver. Taking estradiol may increase the risk of stroke, blood clots, and high blood pressure. It may also cause the body to become more likely to form blood clots, which is seen during both pregnancy and when taking certain birth control pills. The increased risk of high blood pressure is likely caused by estradiol causing the body to retain more sodium.

How Vivelle-Dot works in the body

Estrogen is a hormone found in many of the body's tissues, including the skin, breast, uterus, and brain. In adult women during their reproductive years, the ovarian follicle produces most of the estrogen in the body. After menopause, however, the majority of estrogen is made when androstenedione (a hormone from the adrenal cortex) is converted to estrone in other tissues. Estrone is not as potent as estradiol, the main form of estrogen in premenopausal women, and can cause unpleasant symptoms such as hot flashes and mood swings. When estradiol binds to specific

When to interrupt dosage

The recommended dosage of Vivelle-Dot is contingent upon the established condition, such as Premature Menopause, Pharmaceutical Preparations and Postmenopause. The amount of dosage depends on the method of delivery featured in the table below.

Condition

Dosage

Administration

Breast Cancer

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Prostate Cancer

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Premature Menopause

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Hot Flashes

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Vasomotor System

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Pharmaceutical Preparations

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Palliative Treatment

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Breast

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Therapeutic procedure

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Balanitis Xerotica Obliterans

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

female castration

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Hot flashes

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Hormone Replacement Therapy

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Postmenopause

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Atrophic

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

estradiol

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Amenorrhea

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Hypogonadism

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Osteoporosis

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

hypoestrogenism

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Transdermal, Patch - Transdermal, Ring - Vaginal, Vaginal, Spray, Intramuscular, Patch, extended release, Patch, extended release - Transdermal, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release - Transdermal, Film, extended release, Pellet - Oral, Pellet, Gel - Transdermal, Tablet - Vaginal, Gel, metered - Topical, Ring, Spray - Transdermal, Injection - Intramuscular, Spray, metered, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion - Topical, Emulsion, Capsule, Pellet, implantable - Subcutaneous, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule - Oral, Pellet, implantable

Warnings

Vivelle-Dot Contraindications

Condition

Risk Level

Notes

Breast

Do Not Combine

Angioedema

Do Not Combine

Venous Thrombosis

Do Not Combine

undiagnosed abnormal genital bleeding

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

Liver Dysfunction

Do Not Combine

Breast

Do Not Combine

suspected pregnancy

Do Not Combine

Breast Cancer

Do Not Combine

Pulmonary Embolism

Do Not Combine

Angioedema

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Thromboembolism

Do Not Combine

Neoplasms, Hormone-Dependent

Do Not Combine

Pulmonary Embolism

Do Not Combine

Thromboembolism

Do Not Combine

Thrombophilia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Estradiol may interact with Pulse Frequency

There are 20 known major drug interactions with Vivelle-Dot.

Common Vivelle-Dot Drug Interactions

Drug Name

Risk Level

Description

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Estradiol.

Anagrelide

Major

The metabolism of Anagrelide can be decreased when combined with Estradiol.

Anastrozole

Major

The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estradiol.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Estradiol.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Estradiol.

Vivelle-Dot Toxicity & Overdose Risk

After 90 days, the highest safe dose of estradiol in rats was found to be 0.003 mg/kg/day. If taken in high amounts, estradiol can cause nausea, vomiting, abdominal pain, breast tenderness, blood clots, and abnormal bleeding. In case of overdose, it is advised to stop taking estradiol and seek medical attention.

image of a doctor in a lab doing drug, clinical research

Vivelle-Dot Novel Uses: Which Conditions Have a Clinical Trial Featuring Vivelle-Dot?

867 active clinical trials are currently in progress to assess the capacity of Vivelle-Dot to ameliorate Osteoporosis, Menstrual Absence over the past 6 months and Urogenital Atrophy.

Condition

Clinical Trials

Trial Phases

Hysterectomy

4 Actively Recruiting

Phase 3, Not Applicable

Breast Cancer

19 Actively Recruiting

Phase 2, Phase 1, Not Applicable

estradiol

0 Actively Recruiting

Birth Control

21 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Postmenopause

5 Actively Recruiting

Phase 2, Not Applicable

Metastatic Breast Cancer

1 Actively Recruiting

Phase 1, Phase 2

Osteoporosis, Postmenopausal

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

moderate to severe symptoms

0 Actively Recruiting

Balanitis Xerotica Obliterans

0 Actively Recruiting

Amenorrhea

1 Actively Recruiting

Phase 2

Osteoporosis

28 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Prostate Cancer

71 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Phase 1, Early Phase 1

Breast

0 Actively Recruiting

Urogenital atrophy

0 Actively Recruiting

Low Testosterone

5 Actively Recruiting

Phase 4, Phase 2, Phase 1

Vasomotor System

0 Actively Recruiting

Atrophic Vaginitis

2 Actively Recruiting

Not Applicable, Phase 4

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3

Hormone Replacement Therapy

0 Actively Recruiting

Vivelle-Dot Reviews: What are patients saying about Vivelle-Dot?

5

Patient Review

1/20/2015

Vivelle-Dot for "Change of Life" Signs

I tried Vivelle-Dot 0.05mg after my hysterectomy, but stopped within the first day due to a severe migraine and nausea. The frequency of hot flashes may have decreased slightly, but it was not worth the side effects for me.

5

Patient Review

9/17/2015

Vivelle-Dot for "Change of Life" Signs

After five years of agony, I finally found relief with this medication. I highly recommend it to other women going through menopause.

5

Patient Review

7/12/2015

Vivelle-Dot for "Change of Life" Signs

I've been really pleased with this product. The patch is much smaller than other estrogen patches, and the adhesive has worked well for me.

5

Patient Review

5/14/2016

Vivelle-Dot for Low Estrogen After Operation to Remove Ovaries

I've been using Vivelle Dot since it first came out, and I've tried other prescriptions in pill form from different manufacturers. None of them worked as well as the Vivelle Dot does. I think it's because the Dot is transdermal; it allows me to use a much lower dose while still getting relief.

5

Patient Review

5/21/2016

Vivelle-Dot for "Change of Life" Signs

I use 1.0 mg patch and cut it in 2/3. I have a question for others who have used this treatment: has anyone else experienced itching and numbness at the site of the patch? It's very odd feeling on my left hip where I place my patch every other time (I switch hips each time). Thanks.

5

Patient Review

2/26/2022

Vivelle-Dot for "Change of Life" Signs

I've been on Vivelle Dot for over 25 years and it has drastically improved my quality of life. I highly recommend it to anyone dealing with menopause symptoms.

5

Patient Review

8/1/2015

Vivelle-Dot for Low Estrogen After Operation to Remove Ovaries

I am really pleased with Vivelle Dot. It has eliminated all of my menopause symptoms and I've been sleeping better, skin looks improved, even hair seems to look healthier. Very easy to use and stays on even in the shower. If possible, I would use this for the rest of my life.

5

Patient Review

10/28/2021

Vivelle-Dot for "Change of Life" Signs

I've been using this medication for years with great success. The only problem I ever had was when I switched to a generic brand and it started burning my skin. I went back to the original brand and haven't had any issues since.

4.7

Patient Review

10/24/2017

Vivelle-Dot for Low Estrogen After Operation to Remove Ovaries

I've been on this medication since my hysterectomy in 2000. I get migraines frequently, and I'm not sure if the patches are to blame. However, one doctor said that I might actually experience more without the patch. But when I posed this question to my pharmacist, they explained that 50% of people taking this drug report headaches and migraines. Another downside is that I have experienced a significant weight gain since being on the medication. On the bright side, though, I don't have hot flashes during the day anymore--just at night.

4.3

Patient Review

12/25/2017

Vivelle-Dot for "Change of Life" Signs

Vivelle has been extremely effective in treating my symptoms. The only downside is that I sometimes experience breakthrough bleeding.

4.3

Patient Review

4/4/2016

Vivelle-Dot for Post-Menopausal Osteoporosis Prevention

I've been using this product for over 18 years and it's been working great until recently. I'm 61 now and started having hot flashes and mood swings. The insurance doesn't cover this anymore, so it's quite pricey at $115 a month. Hopefully, I won't have to use it for much longer.

4

Patient Review

1/12/2016

Vivelle-Dot for Low Estrogen After Operation to Remove Ovaries

Easy to use with no side effects. I would advise against using the generic form from Mylan, however. Their patch caused my ears to ring so loudly that it would wake me up from sleep.

4

Patient Review

2/28/2022

Vivelle-Dot for "Change of Life" Signs

I've been using this treatment for three years and have found great success. However, in the summertime I find that the adhesive can get a little too hot and start to seep out. This causes an unsightly mess that's very difficult to remove.

3.3

Patient Review

10/8/2022

Vivelle-Dot for "Change of Life" Signs

I would not recommend this patch to anyone. I used it for three years and ended up with uterine cancer as a result. My Oncologist was very clear that the patch was the cause of my tumor.

3

Patient Review

2/26/2022

Vivelle-Dot for "Change of Life" Signs

This worked well enough for me.

2.3

Patient Review

12/30/2014

Vivelle-Dot for Low Estrogen After Operation to Remove Ovaries

2

Patient Review

3/23/2015

Vivelle-Dot for Low Estrogen After Operation to Remove Ovaries

My doctor put me on this medication after I had a total hysterectomy 7 years ago. I've been very happy not to experience menopause like my friends have. However, I did take myself off the medication for a few weeks just to see what night sweats and hot flashes were like. But I quickly went back on it afterwards.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about vivelle-dot

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long should I use Vivelle-Dot?

"Give the medication Vivelle-Dot either continuously or on a cyclic schedule, depending on whether or not the patient has an intact uterus. If the patient does have an intact uterus, then give Vivelle-Dot on a schedule of 3 weeks on the medication followed by 1 week off the medication."

Answered by AI

Is Vivelle-Dot a natural estrogen?

"The active ingredient in Vivelle-Dot, estradiol, is a form of the hormone estrogen that replaces the estrogen not produced naturally by the ovaries. It is usually applied as a long acting transdermal patch twice a week."

Answered by AI

What is the difference between estradiol patch and Vivelle-Dot?

"If you are experiencing low estrogen levels, Climara (estradiol patch) and Vivelle-Dot (estradiol patch) are both treatment options that only need to be applied once a week. These forms of estrogen may also cause fewer side effects than oral estrogen pills. Menopausal symptoms can also be relieved by using either of these patches."

Answered by AI

What is Vivelle-Dot patch used for?

"The medication is a female hormone that helps to reduce the symptoms of menopause by increasing the levels of estrogen in the body."

Answered by AI

Clinical Trials for Vivelle-Dot

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of Inova Schar Cancer Institute in Fairfax, United States.

Acupuncture for Prostate Cancer

18+
Male
Fairfax, VA

Prostate cancer is the most common cancer among men in the United States. Many men with prostate cancer are treated with hormone therapy, also called androgen deprivation therapy (ADT). While this treatment is effective, it often causes bothersome side effects such as hot flashes, poor sleep, fatigue, and other physical and emotional symptoms. There is currently no standard treatment to help manage these side effects in men. Acupuncture is a non-drug treatment that has been shown to help reduce hot flashes and related symptoms in women receiving hormone therapy for breast cancer. However, much less is known about whether acupuncture is helpful for men receiving hormone therapy for prostate cancer. This study will test whether an acupuncture program, combined with usual lifestyle education, is feasible and acceptable for men undergoing ADT. The study will also explore whether acupuncture may help reduce hot flashes and improve related symptoms. A total of 24 men with prostate cancer receiving ADT will be randomly assigned to one of two groups: one group will begin acupuncture right away, and the other group will begin acupuncture after a delay, with regular check-ins during the waiting period. All participants will receive standard lifestyle education. Participants will be followed for about five months and will be asked to complete daily hot flash diaries, questionnaires about their symptoms and quality of life, and wear a Fitbit to track sleep. The results of this pilot study will help determine whether a larger study should be conducted to better understand the role of acupuncture in managing hormone therapy side effects in men with prostate cancer.

Waitlist Available
Has No Placebo

Inova Schar Cancer Institute

Jeanny Aragon-Ching, MD

Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Waitlist Available
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Quantum Surgical

Have you considered Vivelle-Dot clinical trials?

We made a collection of clinical trials featuring Vivelle-Dot, we think they might fit your search criteria.
Go to Trials
Image of University of Michigan Comprehensive Cancer Center in Ann Arbor, United States.

Self-Monitoring Platform for Cancer

18+
All Sexes
Ann Arbor, MI

This clinical trial evaluates the usefulness of a self-monitoring platform for tracking medication safety events and concerns in patients with lung, colorectal, breast, and prostate cancer. Patients receiving oral anticancer agents often encounter challenges in managing complex treatment regimens, potentially life-threatening toxicities, and drug-drug and drug-food interactions at home. To achieve the goal of medication safety, they need to become "vigilant partners" in medication and toxicity self-monitoring, including timely reporting of medication events to clinicians when their care transitions back home. In this study, patients use an online self-monitoring platform to track their experiences or concerns about taking their medications, including their experiences with symptoms. This platform may be a useful way for patients to track problems they have when taking their medications at home and may help them take better care of their health.

Recruiting
Has No Placebo

University of Michigan Comprehensive Cancer Center

Yun Jiang

Image of University of Waterloo in Waterloo, Canada.

Virtual Chiropractic Intervention for Spinal Fracture

18+
All Sexes
Waterloo, Canada

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Recruiting
Has No Placebo

University of Waterloo

Image of Mayo Clinic in Florida in Jacksonville, United States.

In-Home Treatment for Cancer

18+
All Sexes
Jacksonville, FL

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.

Phase 2
Recruiting

Mayo Clinic in Florida

Roxana S. Dronca, MD

Image of Washington University School of Medicine in St Louis, United States.

Supplemental Imaging for Breast Cancer

25 - 55
Female
St Louis, MO

Recent research has shown that, among women with extremely dense breasts and normal results on mammogram, magnetic resonance imaging (MRI) use has significantly reduced the occurrence of breast cancer that is diagnosed during the time between two regular screening mammograms (also known as interval cancers). The investigators have developed and validated an approach to use the whole mammogram image, develop a mammogram risk score (MRS), and calibrate this to the SEER breast cancer incidence rates for US women. This model (Prognosia Breast) generates an absolute 5-year risk of breast cancer and classifies approximately 5.7% of the population as high risk using the ASCO 3% cut point as used for endocrine therapy to reduce risk. Follow-up generates an incidence of 25.2 cases per 1,000 women per year.

Waitlist Available
Has No Placebo

Washington University School of Medicine

Tabassum Ahmad, M.D.

Have you considered Vivelle-Dot clinical trials?

We made a collection of clinical trials featuring Vivelle-Dot, we think they might fit your search criteria.
Go to Trials
Image of Washington University School of Medicine in St Louis, United States.

Radium-223 for Prostate Cancer

18+
Male
St Louis, MO

Internal radiotherapies (radiolabeled molecules that are systemically administered and localize to sites of disease) provide cancer-ablating doses to diseased cells while sparing adjacent normal tissues. \[223Ra\]RaCl2 (Xofigo) is the first FDA-approved alpha-particle emitting radiopharmaceutical therapy (αRPT), providing a survival benefit for men with bone metastatic castration-resistant prostate cancer. Systemically administered radiotherapies distribute throughout the patient, accumulating to unknown levels at sites of disease and in radiosensitive vital organs. The whole-body distribution means that absorbed doses in the patient extend far beyond a pre-defined treatment field. There is a lack of information about αRPT distribution and localization, and this confounds treatment monitoring, complicates dose and schedule personalization, and impedes drug development. Single-photon emission computed tomography (SPECT) imaging offers a mechanism to quantify uptake; however, αRPT administered activities are significantly lower than those used with diagnostic procedures, which presents a challenge for quantitation with conventional methods. Preliminary research shows that low-count quantitative SPECT (LC-QSPECT) imaging demonstrates reliable quantitation of regional uptake for αRPTs. The purpose of this study is to demonstrate the feasibility, tolerability and performance of LC-QSPECT imaging.

Waitlist Available
Has No Placebo

Washington University School of Medicine

Abhinav K Jha, Ph.D.

Image of City of Hope Medical Center in Duarte, United States.

Oral Cryotherapy for Prostate Cancer

18+
Male
Duarte, CA

This clinical trial studies whether cooling the mouth with popsicles (oral cryotherapy) decreases taste changes in prostate cancer patients receiving taxane chemotherapy. Patients receiving chemotherapy can experience a variety of side effects. Changes in the taste of food is a frequent complaint of patients receiving chemotherapy and is underreported as patients may think that it is unavoidable and not manageable. Taxane-based chemotherapy is thought to be associated with the most taste changes of any chemotherapy. Taste buds contain a specific type of cell, called gustatory cells, that are located on the surface of the tongue, the soft palate (back, muscular part of the roof of the mouth), and the upper part of the esophagus. These cells consist of five basic tastes: salty, sweet, sour, bitter, and umami (or savory). Oral cryotherapy involves cooling the mouth with ice chips, popsicles, or other cold drinks for several minutes before, during, and after chemotherapy causing the tiny blood vessels in the protective linings inside the mouth to narrow. It is thought that this narrowing will reduce blood flow to the cooled areas, thereby decreasing the amount of chemotherapy that is delivered to the fragile protective linings inside the mouth that causes the taste changes. This may be an effective way to decrease taste changes in prostate cancer patients receiving taxane chemotherapy.

Recruiting
Has No Placebo

City of Hope Medical Center

Jeannine M Brant

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Recruiting

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Image of City of Hope Medical Center in Duarte, United States.

Metabolic Interventions for Prostate Cancer

30 - 79
Male
Duarte, CA

This phase II trial compares the effect of time-restricted eating (TRE) and glucagon-like peptide-1 (GLP1) receptor agonists (RA), semaglutide and tirzepatide, to an American Heart Association (AHA) heart healthy diet (HHD) intervention on heart and blood vessel health (cardiovascular system) and how the body processes food for energy (metabolic system) in prostate cancer patients undergoing androgen deprivation therapy (ADT). Prostate cancer patients who are receiving hormonal therapy (ADT) are at an increased risk of cardiovascular disease. This is thought to be due to treatment-related metabolic changes which may result in increased weight, body fat, insulin resistance and an increased risk of heart attack, stroke or other heart and blood vessel problems. TRE (also known as intermittent fasting) is an eating plan that alternates between fasting and non-fasting periods. This approach limits calorie intake to a specific window of time each day. GLP1-RAs, semaglutide and tirzepatide are in a class of medications called incretin mimetics. They work by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. They also slow the movement of food through the stomach and may decrease appetite and cause weight loss. The AHA HHD guidelines may be an effective method to help people learn about following a heart healthy eating plan. This may lower their risk of cardiovascular disease. Metabolic interventions, TRE and GLP1-RA, may be more effective than an AHA HHD intervention alone in improving cardiovascular and metabolic health in prostate cancer patients undergoing ADT.

Phase 2
Recruiting

City of Hope Medical Center

Rose Li

Have you considered Vivelle-Dot clinical trials?

We made a collection of clinical trials featuring Vivelle-Dot, we think they might fit your search criteria.
Go to Trials